An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users

Abstract

Millions of dollars are spent annually to prevent infection with human immunodeficiency virus (HIV) without a thorough understanding of the most effective way to allocate these resources. The authors' objective was to determme the allocation of new resources among prevention programs targeted to a population of injection drug users (IDUs) and a population of non-injection drug users (non-IDUs) that would minimize the total number of incident cases of HIV infection over a given time horizon. They developed a dynamic model of HIV transmission in IDUs and non-IDUs and estimated the rela tionship between prevention program expenditures and reductions in HIV transmission. They evaluated three prevention programs: HIV testing with routine counseling, HIV testing with intensive counseling, and HIV testing and counseling linked to methadone maintenance programs. They modeled a low-risk IDU population (5% HIV prevalence) and a moderate-risk IDU population (10% HIV prevalence). For different available budgets, they determined the allocation of resources among the prevention programs and populations that would minimize the number of new cases of HIV infection over a five-year period, as well as the incremental value of additional prevention funds. The study framework provides a quantitative, systematic approach to funding programs to prevent HIV infection that accounts for HIV transmission dynamics, population size, and the costs and effectiveness of the interventions in reducing HIV transmission. The approach is general and can be used to evaluate a broader group of prevention pro grams and risk populations. This framework thus could enable policy makers and cli nicians to identify a portfolio of programs that provide, collectively, the most benefit for a given budget. Key words: HIV; AIDS; HIV-1; resource allocation; prevention; cost- benefit analysis. (Med Decis Making 1999;19:167-179)

Get full access to this article

View all access options for this article.

References

Who, Unaids. The current global situation of AIDS World Health Organization (available from the Regional Program on AIDS/STD, Pan American Health Organization , 525 23rd St. NW, Washington, DC 20037-2847, 1996

Carpenter CE , Fischl MA , Hammer SM , et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel . JAMA 1997, 227:1962-9.

Deeks SG , Smith M. , Holodniy M. , Kahn JO HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-53

Cohen J. HIV vaccines: are researchers racing towards success, or crawling ? Science. 1994;265:1373-5

Owens DK , Brandeau ML , Sox CH Effect of relapse to high-risk behavior on the costs and benefits of a program to screen women for human immunodeficiency virus (HIV. Interfaces. 1998;28:52-74.

Higgins DL , Galavotti C. , O'Reilly KR , et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991;266:2419-29.

Choi KH , Coates TJ Prevention of HIV infection. AIDS. 1994; 8:1371-89.

Owens DK , Nease RF , Harris RA Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156 394-404

Bennett A. , Sharpe A. Health hazard; AIDS fight is skewed by federal campaign that exaggerated risks; most heterosexuals face scant peril but receive large portion of funds; less goes to gays, addicts. Wall Street Journal. May 1, 1996.A1, A6.

10.

Paltiel AD Timing is of the essence Matching AIDS policy to the epidemic life cycle In: Kaplan EH , Brandeau ML (eds) Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York: Raven Press, 1994:53-71.

11.

May RM , Anderson RM Spatial heterogeneity and the design of immunization programs. Math Biosci. 1984;72:83-111.

12.

Hethcote HW Gonorrhea modeling: a comparison of control methods. Math Biosci. 1982;58:93-109.

13.

Longini IM , Ackerman E. , Elveback LR An optimization model for influenza A epidemics. Math Biosci. 1978;38:141-57.

14.

Sethi SP , Staats PW Optimal control of some simple deterministic epidemic models. J Oper Res Soc. 1978;29:129-36.

15.

Seth SP Optimal quarantine programmes for controlling an epidemic spread. J Oper Res Soc. 1978;29:265-8.

16.

Tan W-Y. , Yakowitz S. Machine learning for Markov decision processes with application to an AIDS allocation program. Systems and Industrial Engineering Department, University of Arizona, Tucson, AZ, 1996.

17.

ReVelle C. , Feldmann F. , Lynn W. An optimization model of tuberculosis epidemiology. Manage Sci. 1969;16:B190-B211.

18.

ReVelle C. , Male J. A mathematical model for determining case finding and treatment activities in tuberculosis control programs. Am Rev Respir Dis. 1970;102:403-11.

19.

Kaplan EH Economic evaluation and HIV prevention community planning—a policy analyst's, perspective. In: Holtgrave DM (ed). Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum (in press).

20.

Richter A. , Brandeau ML Optimal resource allocation for epidemic control among multiple independent populations. Department of Industrial Engineering and Engineering Management, Stanford University, Stanford, CA, 1998.

21.

Washington EA , Showstack JA , Kahn JG , et al. Estimates of the impact and cost of HIV prevention in injection drug users: a report from the Institute for Health Policy Studies, School of Medicine, University of California , San Francisco, Division of STD/HIV Prevention Services, Center for Prevention Services, Center for Disease Control, Atlanta, GA, 1991.

22.

Hartigan PM , Hamilton JD Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system. AIDS Res Human Retroviruses. 1994;10(suppl 2):S215-S217.

23.

Hartigan PM , Hamilton JD , the VA AIDS Vaccine Study Group. Feasibility of enrollment of injection drug users in an HIV seroincidence trial: a VA pilot study. Department of Veterans Affairs, Washington, DC, 1996.

24.

U.S. Bureau of the Census. Statistical Abstract of the United States 1997. Washington, DC: U.S. Government Printing Office, 1997.

25.

Des Jarlais D. , Friedman S. , Sotheran J. , et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA. 1994;271:121-7.

26.

Selwyn P. , Alcabes P. , Hartel D. , et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992; 327:1697-703.

27.

van Haastrecht Hja , van Amijden Ejc , van den Hoek Jar , Mientjes Ghc , Bax JS , Coutinho RA Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users . Am J Epidemiol. 1996;143:380-91.

28.

Pehrson P. , Lindback S. , Lidman C. , Gaines H. , Giesecke J. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS. 1996 ;11:1007-12.

29.

Galli M. , Musicco M. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. COMCAT Study Group. AIDS. 1994;8:1457-63.

30.

Zaric GS , Brandeau ML , Barnett PG Drug abuse treatment and HIV prevention: a cost-effectiveness analysis . Center for Health Care Evaluation, Palo Alto Veteran's Affairs Health Care System, Palo Alto, CA, 1998.

31.

Barnett PG , Rodgers JH The cost of substance abuse treatment from a national survey of treatment programs. Center for Health Care Evaluation, Palo Alto Veterans Affairs Health Care System, Menlo Park, CA , 1998.

32.

Eddy DM Screening for breast cancer. Ann Intern Med. 1989;111:389-99.

33.

Eddy DM Screening for lung cancer. Ann Intern Med. 1989; 111:232-7.

34.

Eddy DM Screening for cervical cancer. Ann Intern Med. 1990;113:214-26.

35.

Goldman L. , Weinstein M. , Goldman P. , Williams L. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991; 265:1145-51.

36.

Matchar DB , Samsa GP , Matthews JR , et al. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med. 1997;127:704-11.

37.

Owens DK , Edwards DE , Shachter RD Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. AIDS. 1998;12:1057-66.

38.

Tsugawa M. , Shachter R. , Owens DK , Parsonnet J. Cost-effectiveness of vaccine development for H. pylori using the Institute-of-Medicine (IOM) Model (abst. Gastroenterology. 1998;114(part 2):G1279.

39.

Parsonnet J. , Harris RA , Hack HH , Owens DK Modeling cost effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials . Lancet. 1996;348: 150-4.

40.

Kaplan EH , O'Keefe E. Let the needles do the talking! Evaluating the New Haven legal needle exchange . Interfaces. 1993;23:7-26.

41.

Holtgrave DR , Qualls NL , Curran JW , Valdiserri RO , Guinan ME , Parra WC An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 1995; 110:134-46.

42.

Holtgrave DM , Reiser WJ , Di Franceisco W. The evaluation of HIV counseling-and-testing services: making the most of limited resources. AIDS Educ Prev. 1997;9:105-18.

43.

Owens DK , Nease Jr RF A normative analytic framework for development of practice guidelines for specific clinical populations. Med Decis Making. 1997;17:409-26.

44.

Nease Jr RF , Owens DK A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making. 1994;14:382-92.

45.

Kahn JG , Brandeau ML , Dunn-Mortimer J. OR modeling and AIDS policy: from theory to practice. Interfaces. 1998;28:3-22.